<DOC>
	<DOC>NCT00204269</DOC>
	<brief_summary>The objective of the study is to examine the efficacy and tolerability of a three-year-Testosterone replacement therapy in hypogonadal patients as well as the patient's compliance. The replacement therapy will be performed with a new Testosterone Gel examined in previous trials as Testosteron Gel Wolff.</brief_summary>
	<brief_title>Three-Year Trial on a New Testosterone Gel</brief_title>
	<detailed_description>The objective of the study is to examine the efficacy and tolerability of a three-year-Testosterone replacement therapy in hypogonadal patients as well as the patient's compliance. The replacement therapy will be performed with a new Testosterone Gel examined in previous trials as Testosteron Gel Wolff (TGW). A minimum of 100 patients will be recruited and evenly distributed to two treatment arms. 1st arm: dermal (non-scrotal) application of TGW. 2nd arm: scrotal application of TGW.</detailed_description>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>men with hypergonadotropic hypogonadism hypogonadotropic hypogonadism lateonset hypogonadism combined with an initial Testosterone serum level of &lt; 11 nmol/l known or suspected carcinoma of the prostate clinically relevant abnormalities in clinical chemistry or haematology any severe medical conditions at the opinion of the investigator</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2006</verification_date>
	<keyword>Hypogonadism</keyword>
	<keyword>Testosterone</keyword>
	<keyword>Substitution</keyword>
</DOC>